Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | Journal of Neuroinflammation

Figure 6

From: Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma

Figure 6

Effects of GSK0660 and GW9662 treatment on palmitoylethanolamide-induced improvement of locomotion after spinal cord injury. The degree of motor disturbance was assessed every day until 10 days after spinal cord injury (SCI) by Basso Mouse Scale (BMS) criteria. Palmitoylethanolamide (PEA)treatment (10 mg/kg) caused a significant increase in Basso, Beattie and Bresnahan (BBB) locomotor rating scale. Pretreatment with GSK0660 (A) or GW9662 (B) abolished PEA-induced improvement of locomotion after SCI. Overall BBB scores of injured PPAR-αKO mice (B) were lower than injured WT mice (A). PEA-treated PPAR-αKO mice did not show a recovery of locomotor function (B).

Back to article page